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Malaria is a major public health problem in Indonesia. Therefore, an effective 
vaccine against this disease is actively being sought by using gamma rays to 
attenuate the parasites. However, the safety and efficacy of the resulting vaccine are
dependent on the precise irradiation dose. The aim of this research was to determine 
the exact time when the parasites are attenuated by gamma ray exposure. Mice 
blood containing Plasmodium berghei of 5,0 X 107 parasites/ml was irradiated with 
gamma rays at doses of 0, 150, 175 and 200 Gy (doses rate of 380 Gy/h) and then 
was injected intraperitoneally to mice at 0, 1, 2, 3, and 4 h post irradiation. The
parasitemia (parasite density) in mouse blood was observed starting with day 2 and 
repeated every 2-4 days up to 28 days. The survival of the mice was also observed 
during the experiment. The results showed that the pre-patent period advanced with 
exposing infected blood to 150 and 175 Gy irradiations, suggesting some degree of 
attenuation. The amount of radiation required to render the parasites non-viable is 
about 175 Gy for an inoculum of a number of parasites, but a delay of 4 h resulted 
in the death of parasites. There was no difference in the infectivity of irradiated 
parasite injected 1 h and 2 h post irradiation in terms of parasitemia and the survival 
of mouse. For a dose of 200 Gy which was injected 2 h post irradiation, no 
parasitemia was found in the blood and animals which died after times varying from 
1 to 4 weeks. We concluded that irradiated parasites should be injected into the host 
within 1 h after irradiation. 
 
© 2013 Atom Indonesia. All rights reserved
 
INTRODUCTION∗ 
 
Malaria kills more than one million people 
each year and is the leading cause of death of 
children in the developing world. Each year, there 
are around 500 million clinical episodes of this 
disease worldwide [1]. Malaria is a mosquito-borne 
disease and hence it can be controlled at the level of 
both human and mosquito. However, malaria 
control is a never-ending battle and requires long-
term sustainability and commitment [2]. Malaria has 
significant impacts on health, social, and economic 
in countries where the disease is endemic [3]. Drug 
treatment is continually undermined by the 
development of drug-resistant parasite strains and 
insecticide resistance of the vector [4]. 
In Indonesia, the achievement of malaria 
control through elimination was done step by step 
from one island to another in order to gain a healthy 
community which is free from malaria transmission 
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by 2030. In the Strategic Plan of the Ministry of 
Health 2010-2014 the malaria control is one target 
by reducing annual paining index from 2 to 1 per 
1.000 people. However in 2009 the index was 1.85 
per 1000 people, so it needs an effective effort such 
as vaccination [5]. In addition to other, existing 
measures, an effective vaccine will be needed to 
achieve eradication of malaria. 
Among the practical applications of 
radiobiological techniques which may be of 
considerable interest for public health is the use of 
ionizing radiation in the preparation of vaccines. 
There has long been an interest at the use of 
attenuated parasite vaccines for malaria control [6], 
and so far the major efforts to develop such whole 
organism vaccines have focused on generating 
attenuated sporozoites by radiation [7,8]. More than 
four decades ago, Ruth Nussenzweig and co-
workers [9] demonstrated that as a result of injection 
of mice with irradiation-attenuated sporozoites, the 
most infectious stage of the rodent malaria parasite 
P. berghei completely prevented onset of blood-
stage parasitemia after challenge. This was a 
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landmark finding which set the standards for 
immunological protection against malaria infection. 
Humans immunized with irradiated P. falciparum 
parasites have been effectively protected from 
subsequent challenge with homologous and 
heterologous infectious P. falciparum [7]. 
Irradiation introduces random mutations and breaks 
in the deoxyribonucleic acid (DNA) of parasites 
[10]. Immunity resulting from immunization with 
irradiated parasites is also multifactorial, includes 
reaction to malaria antigens on infected hepatocytes 
and has cell-mediated components whereas the 
synthetic vaccines do not induce such reactions. 
The successful use of irradiated plasmodium 
as a vaccine depends on finding the radiation dose 
which significantly reduces the pathogenic effect of 
the microorganism without seriously impairing their 
immunogenic power [11]. Besides that, due to live-
attenuated vaccine, the time of injection of 
irradiated parasites into host should be considered; 
thus, this paper presents the results of this study 
which shows that the first one hour post irradiation 
is the best time to inject parasites in terms of 
parasitemia and the survival of the mice. 
 
 
EXPERIMENTAL METHOD 
 
Parasites and mouse 
 
Plasmodium berghei (strain Antwerpen-
Kasapa, ANKA) infected mouse blood batches were 
received from Eijkman Institute for Molecular 
Biology, Indonesian Ministry of Research and 
Technology and National Institute of Health 
Research and Development, Indonesian Ministry of 
Health. Male Swiss-Webster mice Mus musculus 
ssp. (6–8 weeks old) were purchased from the 
National Institute of Health Research and 
Development, Indonesian Ministry of Health, and 
were housed at the animal facility at the Biomedical 
Laboratory of the Center for Technology of 
Radiation Safety and Metrology, National Nuclear 
Energy Agency of Indonesia (BATAN) and handled 
according to institutional guidelines. All procedures 
were reviewed and approved by the Animal Care 
and Use Committee at the National Institute of 
Health Research and Development, the Indonesian 
Ministry of Health. 
 
 
Infection of mouse 
 
The mice were divided into batches, each of 
which consisted of equal numbers of infected               
and control mice. The infected mice were 
intraperitoneally (IP) injected with about 5.0×107 P. 
berghei parasitized blood and control mice were 
sham injected with uninfected blood. Parasitaemia 
was monitored by Giemsa-stained blood smears 
using light microscopy. Parasitaemia and survival of 
mice were evaluated. Mice were sacrificed at days 
post-infection to harvest blood, liver and spleen for 
further analysis. 
 
 
Irradiation of blood stage parasites 
 
Infected batches of mouse blood with 10-25% 
parasitemia were irradiated in vivo inside a gamma 
irradiator (Cobalt-60 of the IRPASENA at the 
Center for Application of Isotope and Radiation, 
BATAN), with doses of 0, 150, 175 and 200 Gy at a 
dose rate of 380.0 Gy/h. The radiation dose was 
calculated from the machine specific estimate of 
1505 Rads per minute. Afterward, the irradiated 
parasites were injected intraperitoneally to mouse at 
various times (0, 1, 2, 3, 4 h) post irradiation. 
During the extension times the irradiated parasites 
were kept in waterbath at 37oC. Unirradiated and/or 
uninfected blood batches served as controls. 
 
 
Parasitemia monitoring 
 
Parasitemias in mice from each infected 
group were monitored started at day 2 and repeated 
every 2-4 days up to 30 days by conventional 
Giemsa staining. Thin blood films were prepared by 
tail bleeding; those blood samples were 
subsequently air dried and methanol fixed before 
staining. Staining was done with a 10% Giemsa 
solution for 10 minutes at room temperature.              
Slides were evaluated at a 1000× magnification               
(oil-immersion) using a Nikon E400 Eclipse 
microscope by reading 20 fields per slide. The total 
number of red blood cells counted was between 
2500 to 6000 cells per treatment. 
 
 
RESULTS AND DISCUSSION 
 
The results of experiments at the 0 h injection 
(directly injected after irradiation) of irradiated 
parasites into mouse showed that the pre-patent 
period advanced with exposing infected blood to 
radiation, suggesting some degree of attenuation, 
except for 200 Gy where parasitemia was 
continuously increased. Higher parasites densities 
were found in mouse injected with 0 Gy irradiation 
where as high as 69.0% of parasitemia was observed 
on day 28 post injection. The amount of radiation 
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required to render the parasites non-viable is about 
175 Gy for an inoculum of a number of parasites 
(Fig. 1). The infectivity of the parasites gradually 
decreased with increasing exposure to irradiation up 
to 175 Gy. For a dose of 200 Gy the parasitemia 
continued to rise until the animals died at times 
which varied from 2 to 5 weeks. To attenuate the 
parasites, the dose of irradiation is the most crucial 
factor. Additionally, another important information 
which is being investigated is the optimal number of 
irradiated parasites needed to obtain a maximal 
protection in mouse in term of parasitemia. 
 
 
 
Fig. 1. The percentage of parasitemia in mouse blood at days 
post injection of irradiated parasited blood 0 h after irradiation. 
Notes that data for 0 and 200 Gy started on day 10 was obtained 
from only 2 surviving mice out of 3 in the initial experiment. 
 
This experiment found that longer pre-patent 
period and lower parasitemia or day of its peak was 
seen on 150 and 175 Gy (Table 1). It is approved 
that live-attenuated parasites with irradiation are 
protective to the host where the contents of parasites 
in red blood cells are low. However there was no 
boost conducted to the primed mice, as done by 
other researchers, to gain the higher degree of 
acquired immunity which is directly proportional to 
the number of immunizing doses [12]. Challenges 
with live parasites is also required to test whether 
the injection of attenuated parasites as vaccine 
materials could elicit an antibody in the host; it is 
the most relevant approach to testing the efficacy of 
experimental malaria vaccines. 
 
Table 1. Pre-patent period, peak of parasitemia and the survival 
time (days) of mouse post injection of irradiated P. berghei 
directly after irradiation. 
 
Dose  
(Gy) 
Pre-patent  
Period 
(day) 
Day of peak of 
parasitemia 
(percentage) 
Survival time 
(day) 
0 2 28 (68.5%) <30 (2 mice) 
150 5 9 (2.2%) >40 
175 5 9 (2.4%) >40 
200 3 28 (54.2%) <35 (2 mice) 
Macroscopic observations, performed 2 
weeks after injection, of the livers and spleens of 
mice directly after irradiation (0 h) showed that 
those organs exhibited fresh colors in mice injected 
with irradiated parasites and in uninfected control 
mice, whereas organs exhibiting much darker 
colors, containing hemoglobin digested by parasites, 
and larger than normal size were found in 0 Gy-
irradiated mice (Fig. 2). These results seem to 
suggest that 175 Gy is the most effective dose for 
attenuating parasites, similar with the finding in the 
percentage of parasitemia in thin blood smear.            
The larger sizes of both organs in 0 Gy-injected 
mouse is due to the increasing number of leucocytes 
leading to splenomegaly during malaria infection 
and increasing the activity of erythropoiesis in 
spleen from abnormal immune response to repeated 
attacks of malaria [13]. 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Macroscopic observations of liver and spleen of mouse 
injected with 0, 150, 175 and 200 Gy irradiated parasites on day 
28 post injection directly (0 h) after irradiation. Control is non 
infected mouse. 
 
In the study on the time of injection after 
irradiation, there was no difference found in the 
infectivity of irradiated parasite injected 1 and 2 h 
post 150 Gy irradiation in terms of parasitemia 
except for day 8 to 12, but it became more 
infectious to the host at 16 and 18 days post 
injection. It is known that the injection of irradiated 
parasites is best conducted within 1 h, preferably 
within 0-30 minutes, after irradiation, as seen in  
Fig. 3. However, no significant difference was 
found between times of injection. 
The percentages of parasitemia in the blood 
of mice injected with 175 Gy irradiated parasites 
whenever injected were lower than 12% in all cases 
and all mice survived during the experiment               
(Fig. 4). Again, this result indicates that irradiation 
of 175 Gy was more effective in attenuating 
parasites compared to 150 Gy. However, injection at 
4 h post irradiation resulted in no parasitemia in any 
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mice, which was most probably due to the mortality 
of parasites before injection. For injections with  
200 Gy-irradiated blood which were injected 2 h 
post irradiation, there was no parasitemia found in 
the blood of animals which died at times varying 
from 1 to 4 weeks (there was no data available for 
the extension times of 3 and 4 h). This implies that 
higher dose of irradiation and longer extension time 
before injection would result in the early death            
of parasites. 
 
 
 
 
Fig. 3. Percentage of parasitemia in mouse blood injected with 
150 Gy irradiated parasites at various times post gamma 
irradiation. 
 
 
 
 
 
Fig. 4. Percentage of parasitemia in mouse blood injected with 
175 Gy irradiated parasites at various times post gamma 
irradiation. 
 
We are developing live-attenuated vaccines 
containing a version of the living microbe which has 
been weakened by ionizing radiation in the lab so it 
cannot cause disease. Because a live-attenuated 
vaccine injection is the most similar event to a 
natural infection, these vaccines are a good learning 
model for the immune system. They elicit strong 
cellular and antibody responses and often confer 
lifelong immunity. Despite the advantages of live-
attenuated vaccines, there are also some 
disadvantages [14]. As found in research activities 
for doses more than 200 Gy, it is the nature of living 
things to change, or mutate, and the organisms used 
in live-attenuated vaccines are no different.             
The remote possibility exists that an attenuated 
microorganism in the vaccine could revert to a 
virulent form and cause disease. Also, not everyone 
can safely receive live-attenuated vaccines. For their 
own protection, people who have damaged or 
weakened immune systems cannot be given live 
vaccines. Another limitation is that live-attenuated 
vaccines usually needs to be refrigerated to stay 
potent. If the vaccine needs to be shipped overseas 
and stored by health care workers in developing 
countries that lack widespread refrigeration, a live 
vaccine may not be the best choice. Live-attenuated 
vaccines are relatively easy to create for certain 
microorganisms. As they evolve to adapt to the new 
environment, they become weaker with respect to 
their natural host, namely human beings [15]. 
Gamma radiation is widely used by many 
researchers to inactivate parasite for the preparation 
of vaccines, instead of traditional heat or chemical 
methods of inactivation. Gamma irradiation appears 
to create a vaccine which is more effective than        
so-called "killed" vaccines against disease, and has 
the added advantage of a longer storage life than 
"live" vaccines. Irradiation is a technically simple 
process which retains the structural features of the 
microbial pathogen without destroying the natural 
antigens or the intrinsic adjuvants. Therefore, a 
strong immune response is induced in the 
vaccinated host. Irradiation destroys the DNA, 
making the microorganism unable to replicate so it 
cannot establish an infection, but some residual 
metabolic activity may survive, so the irradiated 
microorgan-ism can still find its natural target in  
the host [16]. 
The dose of radiation with gamma rays used 
to attenuate plasmodium is the most crucial factor. 
Therefore, determination of the dose of gamma-
irradiation which will produce attenuated parasites 
without affecting the pre-erythrocytic and erythro-
cyte stabilities is the ultimate goal of many studies 
on irradiation vaccine. It is thought that the amount 
of radiation required to render the parasites non-
viable is about 150 Gy for an inoculum of certain 
number of parasites [17,18]. It means that a most 
important step is to determine minimum dose of 
irradiation required to adequately attenuate each 
sporozoite. 
A critical focus of vaccine development 
process has been to determine the minimum dose of 
radiation that adequately attenuates all sporozoites, 
and thus ensures that the vaccine will not cause 
malaria. Researchers are also interested at 
determining the highest dose of radiation that leaves 
the parasites able to elicit optimal protective 
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immunity. For this, Chattopadhyay R. et al. (2008) 
have studied in the Plasmodium yoelii rodent model 
system [19]. Exposure to 100 Gy completely 
attenuated P. yoelii sporozoites after direct injection 
of irradiated parasites. They also demonstrated that 
intravenous immunization of mice with P. yoelii 
sporozoite which had received 200 Gy, double the 
radiation dose required for attenuation, resulted in 
100% protection. These results support the 
contention that a radiation-attenuated sporozoite 
vaccine for malaria will be safe and effective at a 
range of radiation doses and time of injection. 
 
 
CONCLUSION 
 
Irradiation with 150 and 175 Gy at dose rate 
of 380.0 Gy/h was effectively attenuate parasites 
and resulted in longer pre-patent period and the 
survival of mouse. This is supported by macroscopic 
observations. No difference occured in the 
infectiveness of irradiated parasite injected 1 and 2 h 
post irradiation of both doses. It is known that the 
injection of irradiated parasites into mouse should 
be conducted within 1 h or less after irradiation. 
Higher dose of irradiation and longer extension time 
before injection would result in the early death of 
parasites. 
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